A key aspect of the study is the primary focus on ER-positive tumors defined by ≥ 10% positively stained tumor cells, thus excluding the proposed ER-low subgroup of tumors with 1–9% ER staining [10]. The gene discussed is ESR1; the disease is neoplasm.